Konrad H. Stopsack, MD, MPH

Research Associate

Konrad H. Stopsack


MD, University of Freiburg; MPH, Harvard School of Public Health; Internal Medicine Residency, Mayo Clinic Rochester

I am a molecular epidemiologist with a background as a board-certified internal medicine physician. My main research interest is how potentially modifiable exposures cause solid tumors through genomic heterogeneity and influence cancer progression. I am passionate about combining well-defined observational studies and state-of-the-art genomics in order to inform primary prevention, risk stratification, and biomarker-guided treatment. My methodologic and teaching interests include the application of epidemiologic methods to high-dimensional biomarker studies and to clinical studies.

As a Research Associate with Dr. Philip Kantoff’s group, I lead highly interdisciplinary and collaborative research projects across epidemiology, genomics, pathology, bioinformatics, and clinical medicine, with additional experimental validation in cell culture systems. I am the principal investigator of a 2017 Prostate Cancer Foundation Young Investigator Award and a 2018 Department of Defense Early-Investigator Research Award.

As an example of my work on genomic heterogeneity of prostate cancer, I showed that tumors that are very active in synthesizing cholesterol are more likely to metastasize. These results support that cholesterol-lowering statin medications could indeed improve patients’ prognosis, and cholesterol synthesis activity may be a suitable predictive biomarker for clinical trials. In another research lead, I developed methodology to measure the extent of aneuploidy—aberrant numbers of chromosomes—in the tumor transcriptome. We showed that aneuploidy is a strong risk factor for progression to lethal disease, suggesting a potential to better understand the etiology of lethal tumors and to identify therapeutic targets in prostate cancer and beyond.


  1. Drago JZ, Gönen M, Thanarajasingam G, Sacks CA, Morris MJ, Kantoff PW, Stopsack KH. Inferences about drug safety in phase 3 trials in oncology: Examples from advanced prostate cancer. JNCI J Natl Cancer Inst. 2021;113(5):553-561. Journal article with free full text | Accompanying editorial
  2. Stopsack KH, Huang Y, Tyekucheva S, Gerke TA, Bango C, Elfandy H, Bowden M, Penney KL, Roberts TM, Parmigiani G, Kantoff PW, Mucci LA, Loda M. Multiplex immunofluorescence in formalin-fixed paraffin-embedded tumor tissue to identify single cell-level PI3K pathway activation. Clin Cancer Res. 2020;26(22):5903-5913. Journal article | Cover image | Free fulltext
  3. Stopsack KH, Nandakumar S, Wibmer AG, Haywood S, Weg ES, Barnett ES, Kim CJ, Carbone EA, Vasselman SE, Nguyen B, Hullings MA, Scher HI, Morris MJ, Solit DB, Schultz N, Kantoff PW, Abida W. Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer. Clin Cancer Res. 2020;26(13):3230-3238. Journal article | Free fulltext | Results and supplement with hyperlinks | Dataset on cBioPortal
  4. Stopsack KH, Whittaker CA, Gerke TA, Loda M, Kantoff PW, Mucci LA, Amon A. Aneuploidy drives lethal progression in prostate cancer. Proc Natl Acad Sci U S A. 2019;116(23):11390-11395. Journal article with free full text

View a full listing of Konrad H. Stopsack’s journal articles.